|Bid||41.57 x 800|
|Ask||41.58 x 800|
|Day's Range||41.56 - 42.05|
|52 Week Range||40.19 - 45.62|
|Beta (3Y Monthly)||0.45|
|PE Ratio (TTM)||21.45|
|Forward Dividend & Yield||1.74 (4.18%)|
|1y Target Est||52.67|
AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.
(Bloomberg) -- Machine-learning technology has beaten humans at games of chess and Go to worldwide fanfare. A demonstration of its eerily lifelike prowess in making phone calls to unsuspecting people went viral.But a less-noticed win for DeepMind, the artificial-intelligence arm of Google’s parent Alphabet Inc., at a biennial biology conference could upend how drugmakers find and develop new medicines. It could also dial up pressure on the world’s largest pharmaceutical companies to prepare for a technological arms race. Already, a new breed of upstarts are jumping into the fray.In December, at the CASP13 meeting in Riviera Maya, Mexico, DeepMind beat seasoned biologists at predicting the shapes of proteins, the basic building blocks of disease. The seemingly esoteric pursuit has serious implications: A tool that can accurately model protein structures could speed up the development of new drugs. “Absolutely stunning,” tweeted one scientist after the raw results were posted online. “It was a total surprise,” said conference founder John Moult, a University of Maryland computational biologist. “Compared to the history of what we had been able to do, it was pretty spectacular.” Sorting out the structure of proteins in order to find ways for medicines to attack disease is an enormously complex problem. Researchers still don’t fully understand the rules for how proteins are built. And then there’s the math: There are more possible protein shapes than there are atoms in the universe, making prediction a herculean undertaking of computation. For a quarter century, computational biologists have labored to devise software equal to the task.Enter DeepMind. With limited experience in protein folding — the physical process by which a protein acquires its three-dimensional shape — but armed with the latest neural-network algorithms, DeepMind did more than what 50 top labs from around the world could accomplish. Excitement rippled around the Mayan-themed resort where the meeting was held. Two DeepMind presenters were peppered with questions from scientists about how they had done it. Within hours, the British newspaper The Guardian said DeepMind’s AI could “usher in new era of medical progress.” In a blog post, the company bragged that its protein models were “far more accurate than any that have come before,” opening up “new potential within drug discovery.”In an email, DeepMind said its scientists were “fully focused on their research” and not available for interviews. DeepMind’s simulation doesn’t yet produce the kind of atomic-level resolution that is important for drug discovery. And though many companies are looking for ways to use computers to identify new medications, few machine-learning-based drugs have progressed to the point of being tested in humans. It will be years before anyone knows whether such software can regularly spot promising therapies that researchers might otherwise have missed.Artificial intelligence is a chic catchphrase in health care, often trotted out as a cure-all for whatever ails the industry. It has been held up as a potential solution to fix cumbersome electronic medical records, speed up diagnosis and make surgery more precise. DeepMind’s victory points to a possible practical application for the technology in one of the most expensive and failure-prone parts of the pharmaceutical business. Some observers said that the fact that a team of outsiders could make such significant progress in untangling one of the most vexing problems of biology is a black eye for researchers in the field. It could also be a portent for the drug industry, which spends billions on research and development, but was beaten to the punch. Mohammed AlQuraishi, a Harvard computational biology researcher who attended the conference, wrote in a blog post that giant pharmaceutical companies haven’t put a serious effort into protein folding, essentially ceding the ground to tech companies. While drug companies dithered, “Alphabet swoops in and sets up camp right in their backyard,” he wrote.Finding new drugs and bringing them to market is notoriously difficult. According to some estimates, big drugmakers spend more than $2.5 billion to get a new medicine to patients. Just one of every 10 therapies that enters human clinical trials makes it to the pharmacy. And science moves slowly: In the nearly 20 years since the human genome was sequenced, researchers have found treatments for a tiny fraction of the approximately 7,000 known rare diseases.Further, there are approximately 20,000 genes that can malfunction in at least 100,000 ways, and millions of possible interactions between the resultant proteins. It’s impossible for drug hunters to probe all of those combinations by hand.“If we want to understand the other 97 percent of human biology, we will have to acknowledge it is too complex for humans,” said Chris Gibson, the co-founder and Chief Executive Officer of Recursion Pharmaceuticals, a Salt Lake City-based startup that uses machine learning to hunt for new therapies.Companies like Recursion are rapidly luring investors. Venture capitalists poured $1.08 billion into AI and machine-learning startups focused on drug discovery last year, according to data provider PitchBook, up from just $237 million in 2016, and have already put in $699 million more so far this year. Recursion raised $121 million in its latest financing round, the company said on Monday, from investors including Intermountain Ventures and the Regents of the University of Minnesota. It has a valuation of $646 million, according to PitchBook. “It is a very ambitious company. They are thinking in terms of radically changing the industry,” said Marina Record, an investment manager at Baillie Gifford & Co. in Scotland, which led the funding round.Established drugmakers are racing to ally with companies doing similar work.In April, Gilead Sciences Inc. agreed to a deal with Insitro, a startup led by the former Stanford University machine-learning expert Daphne Koller, to find ways to treat liver disease NASH. AstraZeneca Plc the same month linked up with U.K.-based BenevolentAI to identify treatments for kidney disease and lung fibrosis. In June, GlaxoSmithKline Plc partnered with gene-editing pioneers at the University of California in a $67 million target-hunting collaboration that will use AI.“Where else would you accept a 1-in-10 success rate?” said GlaxoSmithKline senior vice president Tony Wood, who heads medicinal science and technology for the British pharmaceutical giant. “If we could double that to 20% it would be phenomenal.” Machine-learning methods “are going to be critical” to drug discovery, said Juan Alvarez, an associate vice president for computational chemistry at Merck & Co. The giant drugmaker is developing AI tools to help its chemists accelerate the laborious process of crafting chemicals to block aberrant proteins. Early machine-learning efforts have already contributed to drugs in human testing, while the first drugs based on more advanced neural-network methods could hit trials in several years, Alvarez said.Artificial intelligence could be used to scan millions of high-resolution cellular images—more than humans could ever process on their own—to identify therapies that could make diseased cells healthier in unexpected ways.At Recursion, one of the earliest startups to use such methods, each week robots apply thousands of potential drugs to various types of diseased cells, in 400,000 to 500,000 miniature experiments that generate 5 to 10 million cellular images. Machine-learning algorithms then scan the images, searching for compounds that disrupt disease without harming healthy cells. The initial algorithms were coded by hand to interpret basic cellular features, but Recursion is increasingly using neural-network methods that directly interpret the images and may spot patterns human programmers wouldn't have looked for. Computer scientists work in tandem with biologists in the laboratory to refine the leads. The company, which has agreed to rare-disease deals with Takeda Pharmaceutical Co. Ltd. and Sanofi, generated more than 2.5 petabytes of data in the past few years, a total that exceeds roughly the bandwidth of all Hollywood feature films. What the company is doing “just wasn't feasible six, or seven, or eight years ago,” said Gibson, its founder. Gibson first turned to machine learning as a graduate student at the University of Utah searching for treatments for cerebral cavernous malformation, which causes abnormal clumps of leaky blood vessels in the brain. The disorder affects about 1 in 500 people, according to the Angioma Alliance, and while often silent, can lead to seizures, speech or vision difficulties, and devastating brain hemorrhages. About a quarter of patients have a genetic form of the illness that is more likely to cause multiple malformations. Even though the three genes that cause it are known, there are no pharmaceutical treatments. One drug Gibson tested at the University of Utah based on the prevailing understanding of the disease made its symptoms worse in animals.Frustrated, Gibson and his colleagues used open-source machine-learning software for scanning cellular images to probe the effects of 2,100 compounds, searching for ones that improved the appearance and function of blood vessel cells that carried the bad genes. The algorithms pointed to an unexpected chemical that reduced leaky blood vessels in animal tests by 50 percent. That drug, set to enter second-stage human trials next year, led to the founding of Recursion.Other parts of Alphabet, as well as the AI research unit of social-media giant Facebook Inc., which quietly released a paper using deep learning to analyze 250 million protein sequences in April, are creeping into pharmaceutical-company turf. This spring, AI researchers at Google unveiled a neural network that can predict the function of a protein from its sequence of amino acids, which can help biologists understand what a newly discovered protein does. AI proponents say that nobody is talking about taking human researchers out of the equation. The goal is “augmenting and enhancing the decision-making capacity of scientists,” said Jackie Hunter, a former GlaxoSmithKline research executive who now leads clinical programs at BenevolentAI. In the short run, it’s more likely that AI-based simulations will be used to game out whether prospective drugs will be effective before going to a full-on clinical trial.An aerospace company “won’t build and fly a plane without building it on the computer first and simulating it under many conditions,” said Colin Hill of GNS Healthcare, a startup using AI to model disease, whose investors include Amgen Inc. In the future, drugmakers won’t begin clinical trials without a virtual dry run, Hill said.Still, the surprise that unfolded in Mexico has increased the tempo. DeepMind “basically beat everyone by a sizeable margin” said AlQuraishi, the Harvard researcher. If drugmakers don’t take the threat seriously, he said, they could be left in the dust. To contact the author of this story: Robert Langreth in New York at email@example.comTo contact the editor responsible for this story: Drew Armstrong at firstname.lastname@example.org, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.
The FDA accepts for review Sanofi's (SNY) BLA for isatuximab as a potential treatment for relapsed/refractory multiple myeloma. The FDA will declare its decision by April 2020.
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 9) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Athenex ...
After its acquisition of Warp Drive Bio last year, this Redwood City biotech company took its cancer-fighting trek into the "undruggable" universe.
Glaxo (GSK) gets an EU approval for Dovato, its single-tablet two-drug HIV regimen. It commences phase III studies on its anti GM-CSF antibody, otilimab, for patients with rheumatoid arthritis.
Most income seekers and retirees have a sort of set playbook when it comes to dividend stocks. They either buy an exchange-traded fund that's heavy in dividend stocks like the iShares Core Dividend Growth ETF (NYSEARCA:DGRO) or they stick to a few well-known dividend stocks like Johnson & Johnson (NYSE:JNJ). And there's nothing wrong with that approach. You certainly can get plenty of income and total return potential from going this route. But income seekers may want to move outside their comfort zone.Specifically, I'm talking about dividend investments that are outside of the U.S.The truth is, some of the best dividend stocks can be found outside the United States. The world is filled with a variety of strong multinational and international leaders. Even better is that valuations for many global stocks are lower than the U.S., while dividend yields are higher.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe yield on the internationally focused MSCI EAFE Index is about double that of the S&P 500. That should be music to an income seeker or retirees' ears. * 10 Stocks That Should Be Every Young Investor's First Choice In the end, going global can result in some wonderful dividends stocks. With that, here are five international dividend stocks to buy today. Unilever (UL, UN)Dividend Yield: 2.96%Suave soap, Ben & Jerry's Ice Cream, Q-tips … these are all brands most people are familiar with. In fact, you probably use some of these brands yourself. That goes to show just how powerful and big Unilever (NYSE:UL, NYSE:UN) is. The firm is a consumer products powerhouse and features 400 different brands and sales in more than 190 different countries.This portfolio of brands continues to pay some big results for UL and its bottom line. Sales continue to rise, jumping 3.1% during the first half of the year. That's not bad for a firm the size of Unilever. The firm has more than 10 brands that generate more than $1 billion in annual sales. So, this is a big ship. Moreover, emerging markets make up a ton of those sales. Here, UL continues to see plenty of growth and high single-digit sale boosts.The future looks rosy for Unilever as well. The firm has announced that it's doing away with its Anglo-Dutch dual share listing and moving to a single share structure. This will reduce costs. Moreover, the firm has undergone some strategic reviews and it has pruned itself of underperforming brands to improve margins and profits.All of this will translate into continued dividend strength. Since moving to a quarterly payout back in 2010, UL has managed to boost its payout by around 90%. This is a testament to its huge portfolio of brands and continued rising sales.Today, Unilever yields nearly 3% making it a top dividend stock to buy. Royal Bank of Canada (RY)Dividend Yield: 3.8%One of the most under-owned nations on the planet happens to be our neighbors to the North. For some reason, Canada isn't included in many international indexes. That's a real shame as the country features plenty of leading dividend stocks and multinational giants.This includes banking giant, the Royal Bank of Canada (NYSE:RY).Historically, Canada's banks have been more conservatively run than U.S. ones. This has been the case for RY for decades. The firm's continued focus on risk management has allowed it to skate through various financial downturns relatively unscathed. Both the Great Recession and the recent Oil Bust didn't affect the bank's bottom line or financial position. This fact has allowed RBC to pay dividends for more than 100 years and keep its payout steady during both crises.But RY isn't a stodgy, old fuddy-duddy. In fact, Canada's banks were some of the first to embrace consumer technology, mobile banking, apps and A.I. Partnerships with tech for its small businesses, enterprise and wealth management divisions have directly boosted retention and overall usage, with digital payments at the bank are surging. All of these digital initiatives have paid off in a big way -- with RY now realizing more than $15 billion in annual revenues. The best part is that RBC now expects to pull in three times the number of new clients as a result of these moves. That'll only grow its base even more. * 10 Stocks to Buy for A Summer Rally For dividend seekers, RY blends the best of both stable revenues with a huge upshot to its growth. With a near-4% yield, it could be one of the best dividend stocks to buy today. GlaxoSmithKline plc (GSK) Dividend Yield: 5.14%When it comes to dividend stocks, Big Pharma offers some of the biggest yields. And the U.K.'s GlaxoSmithKline plc (NYSE:GSK) offers a juicy 5.14% payout. GSK features a robust portfolio of consumer healthcare products with brands such as Aquafresh, Nicorette and Theraflu under its umbrella. However, the firm is also a prescription drug powerhouse with several blockbusters under its belt. Likewise, it has a huge vaccine business that it contains to generate steady revenues.All of this has made GSK a big-time dividend player throughout its history. As a U.K. company, GSK sends out a percentage of profits twice a year, so the amount varies. But it has been steady and consistent.But dividend and growth seekers have a lot to like about GlaxoSmithKline. That's because GSK is currently merging its consumer health division with Pfizer's (NYSE:PFE). This separate company will feature a massive portfolio of brands and produce plenty of stable cash flows. Meanwhile, the remaining biopharma company will feature a robust pipeline of new cancer fighters and other drugs. Investors will be able to get the best of both worlds -- growth and income -- from GSK.Buying GSK today, investors get a seat at the table and the ability to score a high yield. BP PLC (BP)Dividend Yield: 5.85%For a long time, BP (NYSE:BP) was the whipping boy of the energy patch. The Deepwater Horizon spill was horrific and cost billions upon billions of dollars in legal fees, damages and fines. Because of that, BP was pretty much dead for years. But lately, the energy giant has returned to its former glory days … at least in terms of dividends and growth.Thanks to the costs related to the spill, BP was forced to become "lean and mean." That meant selling underperforming and non-core assets, spinning out its logistics infrastructure and reducing its overall debt load. All of this has made the firm a much better run energy stock than before. The results of this made themselves known last summer, when BP actually started to pull in some serious cash flows, Now, BP's operating cash flows currently cover its CAPEX spending and dividend payments when oil is around $50 per barrel.However, with continued technology improvements, BP estimates it should reduce its breakeven price to about $35 per barrel by 2021. With new major finds in the Gulf of Mexico, an increase in onshore shale drilling and other moves, BP is back on the prowl. Since suspending its dividend during the spill, BP has been able to increase its payout by 47% and completely end its so-called script dividend program, which paid investors shares rather than cash. * 7 Marijuana Stocks With Critical Levels to Watch With a near-6% yield, BP makes a strong contender for investors looking for international dividend stocks. iShares International Dividend Growth ETF (IGRO)Dividend Yield: 2.87%Perhaps the best way to get a dose of international dividends is to own them all. We mentioned the popular DGRO ETF in the opening slide. That fund also has an international sister -- the iShares International Dividend Growth ETF (NYSEARCA:IGRO).Similar to DGRO, IGRO tracks a basket of international dividend stocks. The key for the ETF is that it's not just about the payout, but the ability to grow that payout over time. The ETF's index screens for stocks that have been increasing dividends for at least five years straight. A second screen is used to ensure that firms aren't overreaching their ability to pay. Stocks with payout ratios of above 75% are removed. This leaves you with a basket of 408 different dividend stocks. There is some emerging market exposure, but developed markets garner the bulk of assets.Top holdings include pharma giant Sanofi (NYSE:SNY), consumer products superstar Nestle and tech firm Samsung.In terms of performance, IGRO hasn't been bad. The ETF is relatively new -- only opening shop in mid-2016. Since then, it has managed to produce a near-7% return annually. That's not too shabby. Moreover, IGRO yields a very healthy 2.87%. And as a member of iShares core group of funds, expenses for the ETF run at a dirt cheap 0.22%.All in all, when it comes to getting broad exposure to international dividend stocks, IGRO could be one of the best and cheapest ways.At the time of writing, Aaron Levitt did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks That Should Be Every Young Investor's First Choice * 5 IPO Stocks to Buy -- According to Wall Street Analysts * The Top 10 Best Sectors in the Market for 2019 The post 5 Dividend Stocks to Buy From Across the Globe appeared first on InvestorPlace.
(Bloomberg) -- The gauge for the euro-area’s largest listed companies closed in a bull market on Wednesday, extending a rally fueled by the trade truce between the U.S. and China as well as by bets on softer monetary policy.The Euro Stoxx 50 Index gained 0.9% by the close, up about 20% from a late-December low. Equities in the region, led by the tech sector, are getting a boost from the decision by the U.S. and China to resume trade talks. Utilities stocks have also rallied recently amid falling bond yields.An added boost to sentiment is softer rhetoric from global central banks, which last month signaled openness to rate cuts and further stimulus. In the past 24 hours, Christine Lagarde was nominated to take the helm of the European Central Bank later this year, ushering in a candidate whom analysts anticipate will take up departing President Mario Draghi’s mantle in providing stimulus.“The key driving force behind the recent rally has been the unexpected decision by Draghi to announce much greater central bank support than many investors had expected,” said Andrew Milligan, head of global strategy at Aberdeen Standard Investments in Edinburgh. “Looking ahead, we need to see market expectations of easier central bank policy matched by continued good news from the politicians on trade -- or investor sentiment will turn again.”Aberdeen is overweight global equities, but neutral on European stocks because of political risk premia.Some of Wednesday’s biggest advancers included Anheuser-Busch InBev NV, which rose 4.1% after a sale of shares in its Asia Pacific beer unit was priced at the high end of the range. Sanofi added 1.5% after Biocorp said it’s in exclusive talks about introducing its Mallya connected device into the company’s integrated diabetes care platform.“While the European economy remains slow growing with the important manufacturing sector still suffering from a modest recession as global trade stagnates, there are many multinational companies in Europe with solid global operations,” Milligan said.To contact the reporter on this story: Ksenia Galouchko in London at email@example.comTo contact the editors responsible for this story: Blaise Robinson at firstname.lastname@example.org, Paul Jarvis, Jon MenonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Pfizer's (PFE) Eucrisa ointment is found safe in a late-stage label expansion study for treating mild to moderate atopic dermatitis in minors aged 3 months to 2 years.
South Africa's Biovac Institute will start local production of Sanofi's Hexaxim vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said. Local output of the two human vaccines is a step change for Biovac, a public-private partnership 47.5%-owned by the South African government with long-term ambitions of expanding sales into the continent.
Regeneron's (REGN) Dupixent gets favorable recommendation from CHMP for moderate-to-severe atopic dermatitis in adolescents aged 12-17 years.
Novavax (NVAX) seeks to use accelerated approval pathway for its influenza vaccine candidate, NanoFlu, in the United States.
The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.
Regeneron (REGN) and partner Sanofi obtain FDA approval for Dupixent for the treatment of chronic rhinosinusitis with nasal polyposis in adults.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...